SciELO - Scientific Electronic Library Online

 
vol.29 número2Cysticercosis in Colombia. Seroprevalence study 2008-2010Surface electroencephalogram and interictal epileptiform activity in children and teenagers with diagnosis of epilepsy índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Acta Neurológica Colombiana

versão impressa ISSN 0120-8748

Resumo

PAREJA A, Jairo et al. Physical disability in daily clinical practice in multiple sclerosis patients treated with interferon beta-1b. Acta Neurol Colomb. [online]. 2013, vol.29, n.2, pp.87-94. ISSN 0120-8748.

Introduction: multiple sclerosis is the most disabling chronic disease affecting the central nervous system in young adults and characterized by the accumulation of physical disability varying degrees. Objectives: determine the progression of physical disability in patients diagnosed with multiple sclerosis treated with interferon beta-1b. To establish adherence to treatment and safety. Materials and Methods: observational study carried out at 9 neurological centers from the Atlantic Coast of Colombia with patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) or clinically isolated syndrome (CIS) treated with interferon beta-1b.Physical disability was measured with 5 clinical evaluations with Kurtzke´s Expanded Disability Status Scale (EDSS). Results: 83 patients, mean age of 43.4 years (61.5% women). 71.1% of patients had RRMS, 20.1% SPMS and 4.8% CIS. Mean EDSS score remained under 4 (initial 3.7, final 3.5, p=0.712). No differences were found between initial scores and scores after 24 months of observation in patients with RRMS (mean, 3.7 vs 3.4, p=0.424) or SPMS group (mean, 4.0 vs 4.2, p=0.660).17 treatment interruptions occurred. 8.4% of patients experienced adverse events, 4 classified as serious. 2 fatal cases occurred. Conclusion: the functional status of patients with multiple sclerosis treated with interferon beta-1b remained stable without significant changes present in patients with RRMS and SPMS.

Palavras-chave : Chronic Progressive Multiple Sclerosis; Disability Evaluation; Interferon Beta; Relapsing-Remitting Multiple Sclerosis; Retrospective Studies.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )